Practical depth on cell chassis engineering, synthetic biology infrastructure, and production biology for founding science teams.
The choice between starting from a pre-characterized chassis library and building a custom cell line from scratch is one of the first infrastructure decisions an early-stage biotech faces. The answer depends on timeline, budget, and where differentiated value actually lives in your program.
Read article
Titer collapse in CHO cell lines after extended passaging is one of the most common and costly surprises in early mammalian expression programs. Understanding the mechanisms behind instability is the first step toward selecting a chassis baseline that will hold.
Read article
Promoter selection has an outsized effect on soluble yield in bacterial expression systems. This guide covers the practical tradeoffs between T7, Ptrc, Ptac, and ara-based systems for common payload types in early-stage programs.
Read article
Many early-stage programs encounter documentation gaps when moving from research-grade cell banks toward IND-enabling work. This post covers what FDA reviewers look for in a cell bank package and the most common gaps that delay filings.
Read article
The classic CDMO relationship is transactional by design. For early-stage programs building novel cell chassis, a design-partner model — tighter collaboration, shared documentation, and iterative feedback — produces better scientific outcomes at the pre-seed stage.
Read article
The codon adaptation index is a useful starting point, but programs that optimize solely for CAI often encounter ribosome stalling, mRNA instability, and post-translational processing artifacts. A broader optimization framework improves outcomes across host organisms.
Read article
The host organism decision shapes every downstream development step. This framework helps founding teams identify when the glycosylation, folding, and regulatory demands of their target justify the additional complexity of a mammalian system versus a well-characterized microbial chassis.
Read article
When your target protein accumulates intracellularly rather than being secreted, downstream processing costs escalate and product quality suffers. This post covers the key bottlenecks in the secretory pathway and practical engineering strategies to address them.
Read article
Competing metabolic pathways divert carbon away from your target product and reduce theoretical yield. Systematic sink deletion — removing or attenuating non-essential pathways — is one of the highest-leverage modifications in chassis engineering for production strains.
Read article
Microwell screening identifies high-performing constructs, but the transition to stirred-tank bioreactors introduces mass transfer, pH, and dissolved oxygen variables that frequently alter the productivity ranking. Understanding these scale-dependent effects protects the investment in your screening data.
Read article
Genetic constructs under metabolic burden evolve quickly under selection pressure. Without systematic passage monitoring, clonal drift goes undetected until titer or quality metrics collapse. This post outlines the monitoring cadence and diagnostic approaches that flag instability early.
Read article
Engaging an external chassis provider for the first time raises practical questions about what information to share, what milestones to negotiate, and how to structure the technical transfer. This post gives a transparent view of what a well-run partnership looks like from intake to bank delivery.
Read article